Esperion Therapeutics (ESPR) Competitors $2.79 +0.19 (+7.31%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$2.76 -0.02 (-0.90%) As of 08:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. SRPT, MESO, APGE, CDTX, BEAM, TWST, BHVN, IMCR, AUPH, and TVTXShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Sarepta Therapeutics (SRPT), Mesoblast (MESO), Apogee Therapeutics (APGE), Cidara Therapeutics (CDTX), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Biohaven (BHVN), Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Its Competitors Sarepta Therapeutics Mesoblast Apogee Therapeutics Cidara Therapeutics Beam Therapeutics Twist Bioscience Biohaven Immunocore Aurinia Pharmaceuticals Travere Therapeutics Esperion Therapeutics (NASDAQ:ESPR) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Which has better valuation & earnings, ESPR or SRPT? Sarepta Therapeutics has higher revenue and earnings than Esperion Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$332.31M1.69-$51.74M-$0.49-5.69Sarepta Therapeutics$2.48B0.71$235.24M-$0.87-20.59 Is ESPR or SRPT more profitable? Sarepta Therapeutics has a net margin of -2.34% compared to Esperion Therapeutics' net margin of -35.84%. Esperion Therapeutics' return on equity of -0.91% beat Sarepta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-35.84% -0.91% -28.41% Sarepta Therapeutics -2.34%-1.03%-0.37% Does the media prefer ESPR or SRPT? In the previous week, Sarepta Therapeutics had 16 more articles in the media than Esperion Therapeutics. MarketBeat recorded 22 mentions for Sarepta Therapeutics and 6 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 1.20 beat Sarepta Therapeutics' score of 1.13 indicating that Esperion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ESPR or SRPT? Esperion Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Do analysts prefer ESPR or SRPT? Esperion Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 150.90%. Sarepta Therapeutics has a consensus price target of $42.36, suggesting a potential upside of 136.52%. Given Esperion Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Sarepta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Sarepta Therapeutics 6 Sell rating(s) 15 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.07 Do insiders and institutionals have more ownership in ESPR or SRPT? 47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 1.7% of Esperion Therapeutics shares are held by insiders. Comparatively, 7.6% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryEsperion Therapeutics and Sarepta Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.22M$2.55B$5.78B$10.07BDividend YieldN/A56.65%5.69%4.62%P/E Ratio-5.6923.7675.0426.20Price / Sales1.69564.68469.7391.86Price / Cash108.21169.2537.0859.91Price / Book-1.425.3912.236.28Net Income-$51.74M$32.95M$3.29B$270.85M7 Day Performance4.10%2.61%1.53%3.58%1 Month Performance55.87%9.87%7.86%6.67%1 Year Performance59.43%1.49%63.05%27.74% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics4.1246 of 5 stars$2.79+7.3%$7.00+150.9%+60.3%$524.22M$332.31M-5.69200Positive NewsSRPTSarepta Therapeutics4.4678 of 5 stars$18.20-0.8%$43.50+139.0%-86.1%$1.78B$1.90B-20.921,372Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeMESOMesoblast1.5968 of 5 stars$13.83-13.3%$18.00+30.2%+148.7%$1.77B$5.90M0.0080High Trading VolumeAPGEApogee Therapeutics2.9298 of 5 stars$36.37-0.7%$97.29+167.5%-26.4%$1.68BN/A-8.8191News CoveragePositive NewsCDTXCidara Therapeutics3.3128 of 5 stars$65.39+0.2%$64.14-1.9%+458.3%$1.66B$1.27M-5.8890Positive NewsBEAMBeam Therapeutics3.0504 of 5 stars$16.36-2.9%$48.45+196.2%-10.7%$1.66B$60.27M-3.64510TWSTTwist Bioscience4.0011 of 5 stars$26.97+1.4%$49.40+83.2%-42.3%$1.63B$362.27M-18.60990News CoverageBHVNBiohaven3.3012 of 5 stars$15.35-1.1%$54.23+253.2%-60.4%$1.62BN/A-2.00239Trending NewsIMCRImmunocore1.8692 of 5 stars$32.22-0.1%$56.89+76.6%+10.9%$1.62B$356.15M-80.55320AUPHAurinia Pharmaceuticals2.9892 of 5 stars$11.99-0.7%$12.00+0.1%+95.7%$1.58B$235.13M27.88300Positive NewsTVTXTravere Therapeutics3.0091 of 5 stars$17.50-1.1%$33.43+91.0%+104.2%$1.56B$333.87M-8.58460Trending NewsAnalyst Forecast Related Companies and Tools Related Companies Sarepta Therapeutics Competitors Mesoblast Competitors Apogee Therapeutics Competitors Cidara Therapeutics Competitors Beam Therapeutics Competitors Twist Bioscience Competitors Biohaven Competitors Immunocore Competitors Aurinia Pharmaceuticals Competitors Travere Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESPR Stock Alerts